Drugs / p24CE1/2 pDNA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03560258 | Mar 2019 → Feb 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | p24CE1/2 pDNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03560258 ↗ |
| Modality | Vaccine | “p24CE1/2 pDNA vaccine” NCT03560258 ↗ |
| Route | Other | “administered by one injection/electroporation” NCT03560258 ↗ |